The estimated Net Worth of W Thorpe Mckenzie is at least 27.1 百万$ dollars as of 16 December 2021. Mr. Mckenzie owns over 250,000 units of XBiotech Inc stock worth over 18,186,937$ and over the last 9 years he sold XBIT stock worth over 8,795,003$. In addition, he makes 137,000$ as Independent Director at XBiotech Inc.
W has made over 17 trades of the XBiotech Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 250,000 units of XBIT stock worth 2,500,000$ on 16 December 2021.
The largest trade he's ever made was selling 385,000 units of XBiotech Inc stock on 4 October 2018 worth over 1,155,000$. On average, W trades about 52,907 units every 68 days since 2015. As of 16 December 2021 he still owns at least 2,810,964 units of XBiotech Inc stock.
You can see the complete history of Mr. Mckenzie stock trades at the bottom of the page.
W. Thorpe Jerome McKenzie serves as Independent Director of the Company. Mr. McKenzie served as Managing Director of Pointer Management Company, Chattanooga, Tennessee, since its inception in July 1990 until December 31, 2015, and as of January 1, 2016, serves as its Senior Advisor. Mr. McKenzie co-founded Pointer Management Company in July 1990 to invest in hedge funds and similar types of partnerships utilizing a fund of funds approach. From August 1982 until June 1990, he was a private investor in New York City, and a director of several public and private companies. From May 1980 until July 1982, he was founding general partner at TIGER, a global hedge fund. From May 1971 until January 1980, he was a Vice President of Kidder, Peabody & Co., Inc. in New York. Mr. McKenzie is a graduate of the University of North Carolina in Chapel Hill and the Wharton Graduate division of the University of Pennsylvania in Philadelphia.
As the Independent Director of XBiotech Inc, the total compensation of W McKenzie at XBiotech Inc is 137,000$. There are 6 executives at XBiotech Inc getting paid more, with John Simard having the highest compensation of 10,810,400$.
W McKenzie is 72, he's been the Independent Director of XBiotech Inc since 2018. There are 1 older and 8 younger executives at XBiotech Inc. The oldest executive at XBiotech Inc is Peter Libby, 73, who is the Independent Director.
W's mailing address filed with the SEC is 832 GEORGIA AVENUE, SUITE 1100, CHATTANOOGA, TN, 37402.
Over the last 9 years, insiders at XBiotech Inc have traded over 50,443,920$ worth of XBiotech Inc stock and bought 1,428,502 units worth 11,921,113$ . The most active insiders traders include Street Financial S.A. Bay、Fondation Rennes、W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of 1,053,782$. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth 2,500,000$.
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
XBiotech Inc executives and other stock owners filed with the SEC include: